Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 135 entries
Sorted by: Best Match Show Resources per page
Renal biopsy cases in myeloproliferative neoplasms (MPN).

CEN case reports

Fujita K, Hatta K.
PMID: 28509296
CEN Case Rep. 2013 Nov;2(2):215-221. doi: 10.1007/s13730-013-0067-0. Epub 2013 Mar 12.

We performed renal biopsy in three cases complicated by myeloproliferative neoplasms (MPN). Although several cases of glomerulonephritis associated with MPN have been reported, the etiologies of the renal disorders were not established (Plomley et al., Aust NZ J Med,...

Cite
Fujita K, Hatta K. Renal biopsy cases in myeloproliferative neoplasms (MPN). CEN Case Rep. 2013;2(2):215-221doi: 10.1007/s13730-013-0067-0.
Fujita, K., & Hatta, K. (2013). Renal biopsy cases in myeloproliferative neoplasms (MPN). CEN case reports, 2(2), 215-221. https://doi.org/10.1007/s13730-013-0067-0
Fujita, Kumi, and Hatta, Kazuhiro. "Renal biopsy cases in myeloproliferative neoplasms (MPN)." CEN case reports vol. 2,2 (2013): 215-221. doi: https://doi.org/10.1007/s13730-013-0067-0
Fujita K, Hatta K. Renal biopsy cases in myeloproliferative neoplasms (MPN). CEN Case Rep. 2013 Nov;2(2):215-221. doi: 10.1007/s13730-013-0067-0. Epub 2013 Mar 12. PMID: 28509296; PMCID: PMC5411553.
Copy Download .nbib Format: NLM
Erratum.

American journal of nephrology

[No authors listed]
PMID: 31295742
Am J Nephrol. 2019;50(2):160. doi: 10.1159/000501980. Epub 2019 Jul 11.

No abstract available.

Cite
Erratum. Am J Nephrol. 2019;50(2):160doi: 10.1159/000501980.
(2019). Erratum. American journal of nephrology, 50(2), 160. https://doi.org/10.1159/000501980
"Erratum." American journal of nephrology vol. 50,2 (2019): 160. doi: https://doi.org/10.1159/000501980
Erratum. Am J Nephrol. 2019;50(2):160. doi: 10.1159/000501980. Epub 2019 Jul 11. PMID: 31295742; PMCID: PMC7903859.
Copy Download .nbib Format: NLM
Prediction of Chronic Kidney Disease Progression by Magnetic Resonance Imaging: Where Are We?.

American journal of nephrology

Jiang K, Lerman LO.
PMID: 30630177
Am J Nephrol. 2019;49(2):111-113. doi: 10.1159/000496160. Epub 2019 Jan 10.

No abstract available.

Cite
Jiang K, Lerman LO. Prediction of Chronic Kidney Disease Progression by Magnetic Resonance Imaging: Where Are We?. Am J Nephrol. 2019;49(2):111-113doi: 10.1159/000496160.
Jiang, K., & Lerman, L. O. (2019). Prediction of Chronic Kidney Disease Progression by Magnetic Resonance Imaging: Where Are We?. American journal of nephrology, 49(2), 111-113. https://doi.org/10.1159/000496160
Jiang, Kai, and Lerman, Lilach O. "Prediction of Chronic Kidney Disease Progression by Magnetic Resonance Imaging: Where Are We?." American journal of nephrology vol. 49,2 (2019): 111-113. doi: https://doi.org/10.1159/000496160
Jiang K, Lerman LO. Prediction of Chronic Kidney Disease Progression by Magnetic Resonance Imaging: Where Are We?. Am J Nephrol. 2019;49(2):111-113. doi: 10.1159/000496160. Epub 2019 Jan 10. PMID: 30630177; PMCID: PMC7304632.
Copy Download .nbib Format: NLM
Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study.

American journal of nephrology

Barreto EF, Schreier DJ, May HP, Mara KC, Chamberlain AM, Kashani KB, Piche SL, Wi CI, Kane-Gill SL, Smith VT, Rule AD.
PMID: 34727542
Am J Nephrol. 2021;52(10):817-826. doi: 10.1159/000519375. Epub 2021 Nov 02.

INTRODUCTION: Acute kidney injury (AKI) affects 20% of hospitalized patients and worsens outcomes. To limit complications, post-discharge follow-up and kidney function testing are advised. The objective of this study was to evaluate the frequency of follow-up after discharge among...

Cite
Barreto EF, Schreier DJ, May HP, et al. Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. Am J Nephrol. 2021;52(10):817-826doi: 10.1159/000519375.
Barreto, E. F., Schreier, D. J., May, H. P., Mara, K. C., Chamberlain, A. M., Kashani, K. B., Piche, S. L., Wi, C. I., Kane-Gill, S. L., Smith, V. T., Rule, A. D. (2021). Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. American journal of nephrology, 52(10), 817-826. https://doi.org/10.1159/000519375
Barreto, Erin F, et al. "Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study." American journal of nephrology vol. 52,10 (2021): 817-826. doi: https://doi.org/10.1159/000519375
Barreto EF, Schreier DJ, May HP, Mara KC, Chamberlain AM, Kashani KB, Piche SL, Wi CI, Kane-Gill SL, Smith VT, Rule AD. Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. Am J Nephrol. 2021;52(10):817-826. doi: 10.1159/000519375. Epub 2021 Nov 02. PMID: 34727542; PMCID: PMC8665070.
Copy Download .nbib Format: NLM
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.

American journal of nephrology

Lam D, Nadkarni GN, Mosoyan G, Neal B, Mahaffey KW, Rosenthal N, Hansen MK, Heerspink HJL, Fleming F, Coca SG.
PMID: 35016188
Am J Nephrol. 2022 Jan 11;1-11. doi: 10.1159/000519920. Epub 2022 Jan 11.

INTRODUCTION: KidneyIntelX is a composite risk score, incorporating biomarkers and clinical variables for predicting progression of diabetic kidney disease (DKD). The utility of this score in the context of sodium glucose co-transporter 2 inhibitors and how changes in the...

Cite
Lam D, Nadkarni GN, Mosoyan G, et al. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. Am J Nephrol. 2022;1-11doi: 10.1159/000519920.
Lam, D., Nadkarni, G. N., Mosoyan, G., Neal, B., Mahaffey, K. W., Rosenthal, N., Hansen, M. K., Heerspink, H. J. L., Fleming, F., & Coca, S. G. (2022). Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. American journal of nephrology, 1-11. https://doi.org/10.1159/000519920
Lam, David, et al. "Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial." American journal of nephrology vol. (2022): 1-11. doi: https://doi.org/10.1159/000519920
Lam D, Nadkarni GN, Mosoyan G, Neal B, Mahaffey KW, Rosenthal N, Hansen MK, Heerspink HJL, Fleming F, Coca SG. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. Am J Nephrol. 2022 Jan 11;1-11. doi: 10.1159/000519920. Epub 2022 Jan 11. PMID: 35016188.
Copy Download .nbib Format: NLM
Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease.

American journal of nephrology

Goldberg A, Garcia-Arroyo F, Sasai F, Rodriguez-Iturbe B, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ.
PMID: 34673651
Am J Nephrol. 2021;52(10):837-844. doi: 10.1159/000519491. Epub 2021 Oct 21.

Hyperuricemia predicts the development of chronic kidney disease (CKD) and metabolic complications, but whether it has a causal role has been controversial. This is especially true given the 2 recently conducted randomized controlled trials that failed to show a...

Cite
Goldberg A, Garcia-Arroyo F, Sasai F, et al. Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease. Am J Nephrol. 2021;52(10):837-844doi: 10.1159/000519491.
Goldberg, A., Garcia-Arroyo, F., Sasai, F., Rodriguez-Iturbe, B., Sanchez-Lozada, L. G., Lanaspa, M. A., & Johnson, R. J. (2021). Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease. American journal of nephrology, 52(10), 837-844. https://doi.org/10.1159/000519491
Goldberg, Avi, et al. "Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease." American journal of nephrology vol. 52,10 (2021): 837-844. doi: https://doi.org/10.1159/000519491
Goldberg A, Garcia-Arroyo F, Sasai F, Rodriguez-Iturbe B, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ. Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease. Am J Nephrol. 2021;52(10):837-844. doi: 10.1159/000519491. Epub 2021 Oct 21. PMID: 34673651; PMCID: PMC8665019.
Copy Download .nbib Format: NLM
Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999-2014 NHANES Analysis.

American journal of nephrology

Li WL, Zhang NH, Ge SW, Xu G.
PMID: 34839290
Am J Nephrol. 2021 Nov 26;1-10. doi: 10.1159/000520027. Epub 2021 Nov 26.

INTRODUCTION: High risk of early death, especially contributed to cardiovascular disease, exists in patients who have chronic kidney disease (CKD). And the burden of cardiovascular disease is able to be lightened by an increase in omega-3 polyunsaturated fatty acid...

Cite
Li WL, Zhang NH, Ge SW, et al. Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999-2014 NHANES Analysis. Am J Nephrol. 2021;1-10doi: 10.1159/000520027.
Li, W. L., Zhang, N. H., Ge, S. W., & Xu, G. (2021). Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999-2014 NHANES Analysis. American journal of nephrology, 1-10. https://doi.org/10.1159/000520027
Li, Wei-Lan, et al. "Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999-2014 NHANES Analysis." American journal of nephrology vol. (2021): 1-10. doi: https://doi.org/10.1159/000520027
Li WL, Zhang NH, Ge SW, Xu G. Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999-2014 NHANES Analysis. Am J Nephrol. 2021 Nov 26;1-10. doi: 10.1159/000520027. Epub 2021 Nov 26. PMID: 34839290.
Copy Download .nbib Format: NLM
Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol.

American journal of nephrology

Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, Bishop CW, Ashfaq A.
PMID: 34818216
Am J Nephrol. 2021;52(10):798-807. doi: 10.1159/000518545. Epub 2021 Oct 27.

INTRODUCTION: The safety and efficacy of extended-release calcifediol (ERC) as a treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI) has been demonstrated in prospective randomized clinical...

Cite
Fadda G, Germain MJ, Broumand V, et al. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. Am J Nephrol. 2021;52(10):798-807doi: 10.1159/000518545.
Fadda, G., Germain, M. J., Broumand, V., Nguyen, A., McGarvey, N., Gitlin, M., Bishop, C. W., & Ashfaq, A. (2021). Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. American journal of nephrology, 52(10), 798-807. https://doi.org/10.1159/000518545
Fadda, George, et al. "Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol." American journal of nephrology vol. 52,10 (2021): 798-807. doi: https://doi.org/10.1159/000518545
Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, Bishop CW, Ashfaq A. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. Am J Nephrol. 2021;52(10):798-807. doi: 10.1159/000518545. Epub 2021 Oct 27. PMID: 34818216.
Copy Download .nbib Format: NLM
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease.

American journal of nephrology

Ciardullo S, Ballabeni C, Trevisan R, Perseghin G.
PMID: 34569517
Am J Nephrol. 2021;52(8):666-672. doi: 10.1159/000518111. Epub 2021 Sep 16.

INTRODUCTION: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to...

Cite
Ciardullo S, Ballabeni C, Trevisan R, et al. Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease. Am J Nephrol. 2021;52(8):666-672doi: 10.1159/000518111.
Ciardullo, S., Ballabeni, C., Trevisan, R., & Perseghin, G. (2021). Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease. American journal of nephrology, 52(8), 666-672. https://doi.org/10.1159/000518111
Ciardullo, Stefano, et al. "Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease." American journal of nephrology vol. 52,8 (2021): 666-672. doi: https://doi.org/10.1159/000518111
Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease. Am J Nephrol. 2021;52(8):666-672. doi: 10.1159/000518111. Epub 2021 Sep 16. PMID: 34569517.
Copy Download .nbib Format: NLM
Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model.

American journal of nephrology

Hering D, Hubbard BS, Weber MA, Heuser RR.
PMID: 34038910
Am J Nephrol. 2021;52(5):429-434. doi: 10.1159/000516186. Epub 2021 May 26.

INTRODUCTION: The blood pressure (BP) response to arterial renal denervation (RDN) is variable.METHODS: This study examined the effectiveness of renal pelvic denervation (RPD) on BP, heart rate (HR), norepinephrine (NE), and histopathology in 42 swine. NE levels were measured...

Cite
Hering D, Hubbard BS, Weber MA, et al. Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. Am J Nephrol. 2021;52(5):429-434doi: 10.1159/000516186.
Hering, D., Hubbard, B. S., Weber, M. A., & Heuser, R. R. (2021). Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. American journal of nephrology, 52(5), 429-434. https://doi.org/10.1159/000516186
Hering, Dagmara, et al. "Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model." American journal of nephrology vol. 52,5 (2021): 429-434. doi: https://doi.org/10.1159/000516186
Hering D, Hubbard BS, Weber MA, Heuser RR. Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. Am J Nephrol. 2021;52(5):429-434. doi: 10.1159/000516186. Epub 2021 May 26. PMID: 34038910.
Copy Download .nbib Format: NLM
Retraction Statement.

American journal of nephrology

[No authors listed]
PMID: 34554122
Am J Nephrol. 2021;52(7):604. doi: 10.1159/000519103. Epub 2021 Aug 27.

No abstract available.

Cite
Retraction Statement. Am J Nephrol. 2021;52(7):604doi: 10.1159/000519103.
(2021). Retraction Statement. American journal of nephrology, 52(7), 604. https://doi.org/10.1159/000519103
"Retraction Statement." American journal of nephrology vol. 52,7 (2021): 604. doi: https://doi.org/10.1159/000519103
Retraction Statement. Am J Nephrol. 2021;52(7):604. doi: 10.1159/000519103. Epub 2021 Aug 27. PMID: 34554122.
Copy Download .nbib Format: NLM
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

American journal of nephrology

Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, Droebner K, Joseph A, Hüser J, Eitner F.
PMID: 34111864
Am J Nephrol. 2021;52(8):642-652. doi: 10.1159/000516213. Epub 2021 Jun 10.

INTRODUCTION: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing the potential value of a combination therapy are currently limited. We therefore...

Cite
Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-652doi: 10.1159/000516213.
Kolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021). Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. American journal of nephrology, 52(8), 642-652. https://doi.org/10.1159/000516213
Kolkhof, Peter, et al. "Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage." American journal of nephrology vol. 52,8 (2021): 642-652. doi: https://doi.org/10.1159/000516213
Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, Droebner K, Joseph A, Hüser J, Eitner F. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-652. doi: 10.1159/000516213. Epub 2021 Jun 10. PMID: 34111864; PMCID: PMC8619789.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 135 entries